Tests for suspected thalassemia: moving from a blood count to hemoglobin and genetic confirmation

A small red-cell size on a routine blood count, persistent pallor in a child, and a positive carrier result during pregnancy lead to different clinical questions. The person attending a routine checkup may need to distinguish a carrier state from iron deficiency. An unwell child needs an assessment of the illness and any immediate support required. A couple planning a pregnancy needs an explanation of how their particular results interact. A useful investigation plan starts with the question that must be answered, rather than the largest available collection of tests. NHLBI: Thalassemia diagnosis

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Tell the clinician when anemia was first noticed, whether jaundice has occurred, and how symptoms affect ordinary activities. For children, growth records and the age at which symptoms began may be particularly informative. A family history of long-standing anemia, an enlarged spleen, regular transfusions, or a known hemoglobin disorder can help, but the absence of such a history does not exclude thalassemia. Relatives with a carrier state may never have had a reason to be tested. Langer: Beta-Thalassemia, GeneReviews, revision February 12, 2026
“No variant detected” describes the findings within a test's scope. It does not necessarily mean that every relevant gene alteration has been excluded. If the blood findings and family information remain strongly suggestive, the team may review the original analytical method, obtain complementary testing, or investigate another explanation. Additional testing should resolve a defined uncertainty rather than continue until an incidental abnormality appears. ARUP Consult: Thalassemias, updated April 2026
Before leaving, ask whether the present conclusion is a carrier state, a confirmed clinically significant disorder, or an unresolved finding. Identify which results are dependable and which may be affected by age, transfusion, or another condition. The next proposed test should have a stated purpose and an explanation of how its result could change care. NHLBI: Thalassemia diagnosis

Quick answer

Full guide

Start with the history that changes how a sample is interpreted

Tell the clinician when anemia was first noticed, whether jaundice has occurred, and how symptoms affect ordinary activities. For children, growth records and the age at which symptoms began may be particularly informative. A family history of long-standing anemia, an enlarged spleen, regular transfusions, or a known hemoglobin disorder can help, but the absence of such a history does not exclude thalassemia. Relatives with a carrier state may never have had a reason to be tested. Langer: Beta-Thalassemia, GeneReviews, revision February 12, 2026

Make a separate list of blood transfusions, including dates, where they were given, and any available records. Transfused donor cells can change the mixture of hemoglobins measured in a recent sample. The laboratory needs this information before interpreting an apparently reassuring or unusual hemoglobin pattern. Patients should not withhold a medically necessary transfusion to obtain a supposedly cleaner screening result. The clinical team can consider earlier samples, appropriate molecular testing, and the timing of later investigations while treating the immediate problem. ARUP Consult: Thalassemias, updated April 2026 Shah, Wood and Maggio: Blood Transfusion, TIF 2025

Medicines and supplements also belong in the history. Iron taken for several months, previous chelation, and treatment for a recent infection provide context that a laboratory number cannot supply on its own. Bringing the complete older reports is preferable to reconstructing them from memory.

A complete blood count is a starting point, not a genetic diagnosis

The first assessment commonly includes hemoglobin concentration, red-cell size and hemoglobin content, the red-cell count, other blood-cell lines, and a blood film. Small, relatively pale red cells can occur in thalassemia and in iron deficiency. Some carriers have little or no reduction in their overall hemoglobin concentration. Consequently, a normal-looking hemoglobin result cannot by itself rule out a carrier state, and a low mean cell volume cannot by itself establish thalassemia. Origa et al.: Genetic Basis, Pathophysiology, and Diagnosis, TIF 2025

Online calculators sometimes use the mean cell volume and red-cell count to suggest whether iron deficiency or thalassemia is more likely. Such indices are screening aids with limitations. Coexisting conditions and patient age can alter their usefulness. They should not determine years of iron supplementation, cancel a genetic consultation, or be used to predict an unborn child's condition. A clinician needs the pattern of results and the patient's circumstances. ARUP Consult: Thalassemias, updated April 2026

Ask for an explanation in ordinary terms: which findings suggest reduced red-cell production, which suggest an inherited hemoglobin condition, and whether another blood disorder needs consideration. This makes the next investigation easier to understand than focusing only on the numbers highlighted in red.

Investigate iron deficiency as its own question

Iron studies help assess whether iron deficiency contributes to the blood-count findings. Ferritin must be interpreted in context because inflammation and other conditions can influence it. A thalassemia carrier can also have iron deficiency from inadequate intake, menstrual loss, or another source of blood loss. Discovering a carrier state does not remove the need to investigate an otherwise unexplained change in hemoglobin. Equally, persistent microcytosis alone is not a reason to continue iron indefinitely. ARUP Consult: Thalassemias, updated April 2026 Porter, Wood and Coates: Iron Overload and Chelation, TIF 2025

The clinical context differs substantially between a healthy person who has never been transfused and someone receiving regular red-cell transfusions and chelation. A result that is useful for one person's diagnostic workup may serve a different purpose in the other person's treatment monitoring. Families should avoid comparing isolated ferritin results across these groups.

List the ingredients of multivitamins and traditional or over-the-counter products as well as prescribed medicines. Nutritional assessment should identify actual deficiencies and eating difficulties. It does not require the same supplements for every person whose blood count carries a thalassemia label. Fung and Angastiniotis: Nutrition, TIF 2025

Hemoglobin testing examines a mixture that changes with age and treatment

Laboratories may use high-performance liquid chromatography, capillary electrophoresis, or complementary techniques to assess hemoglobin fractions and variants. HbA, HbA2, and HbF can provide important clues, particularly for beta-thalassemia, but a single method does not identify every possible variant. A newborn's hemoglobin composition also differs from an adult's and changes during infancy. Age-appropriate interpretation is essential. Origa et al.: Genetic Basis, Pathophysiology, and Diagnosis, TIF 2025 ARUP Consult: Thalassemias, updated April 2026

Recent transfusion introduces donor hemoglobin into the sample. Severe iron deficiency can affect interpretation of HbA2. These are reasons for a careful laboratory comment, not reasons to assume that any uncertain result proves a severe disorder. If a report recommends confirmation, ask whether the issue is a possible interfering factor, a fraction that needs a second analytical method, or a suspected variant requiring genetic characterization. ARUP Consult: Thalassemias, updated April 2026

A result described as a variant peak is not interchangeable with a fully identified pathogenic variant. Request the final interpretive report rather than relying on a photograph of a graph. When several methods have been used, the laboratory's integrated conclusion is more useful than judging each measurement separately.

Alpha-thalassemia may need molecular testing despite an unremarkable hemoglobin profile

Some adults with alpha-thalassemia carrier states have hemoglobin-analysis results that are close to normal. Persistent small red cells, a relevant family result, or reproductive screening concerns may therefore justify further assessment even when the hemoglobin fractions do not provide an obvious answer. Testing may involve common-deletion analysis, broader deletion and duplication methods, and sequencing, depending on the question and the laboratory. A negative panel covering only selected common variants does not exclude every alpha-globin abnormality. GeneReviews: Alpha-Thalassemia, current review

The number of affected alpha-globin genes matters, but so does their arrangement and the type of alteration involved. Deletional and nondeletional forms should not be treated as interchangeable. A short result reading only “alpha-thalassemia positive” is often inadequate for a reproductive consultation or for explaining a person's clinical course. TIF 2023: α-Thalassaemia guideline, summary and recommendations

HbH disease warrants assessment of anemia, hemolysis, illness-related worsening, and the wider clinical history. It should not be dismissed as an incidental carrier finding merely because it involves alpha rather than beta globin. Conversely, finding a carrier genotype does not establish that every symptom the person experiences is caused by thalassemia.

Beta-thalassemia testing needs both molecular and clinical interpretation

HBB analysis can help establish beta-thalassemia and clarify related hemoglobin disorders. Most relevant variants and less common structural changes are not necessarily detected by exactly the same method, so the laboratory's coverage matters. The presence of an HBB result alone does not determine whether a particular patient will require lifelong regular transfusions. Langer: Beta-Thalassemia, GeneReviews, revision February 12, 2026

Clinicians also assess age, the long-term hemoglobin pattern, symptoms, growth, complications, and transfusion requirements. A blood transfusion during a serious infection does not, by itself, classify someone as having transfusion-dependent thalassemia. HbE/beta-thalassemia can have a wide clinical range and deserves an explanation that connects the molecular result with the individual patient. Taher, Musallam and Cappellini: NTDT guideline introduction, third edition, 2023 Origa et al.: Genetic Basis, Pathophysiology, and Diagnosis, TIF 2025

The distinction between identifying the inherited disorder and classifying current treatment needs is useful. The first can be established with laboratory and genetic evidence; the second may require observation over time. A family's care plan can evolve without implying that the original genetic test was incorrect.

Understand what negative and uncertain results actually mean

“No variant detected” describes the findings within a test's scope. It does not necessarily mean that every relevant gene alteration has been excluded. If the blood findings and family information remain strongly suggestive, the team may review the original analytical method, obtain complementary testing, or investigate another explanation. Additional testing should resolve a defined uncertainty rather than continue until an incidental abnormality appears. ARUP Consult: Thalassemias, updated April 2026

A variant of uncertain significance should not automatically be treated as a confirmed disease-causing result. Its classification, family evidence, and consistency with the clinical findings all matter. Keep the full laboratory report, including the method, coverage, interpretation, and any limitations. A single line containing the word “mutation” can omit precisely the information needed to make a responsible decision. Langer: Beta-Thalassemia, GeneReviews, revision February 12, 2026 GeneReviews: Alpha-Thalassemia, current review

When reports appear to disagree, ask the clinician to identify the disagreement clearly. One test may have examined common deletions while another examined sequence changes; another may have been performed after a transfusion. Explaining the scope and timing is often more productive than repeating an identical test without a new clinical question.

Partner testing and genetic counseling should make the inheritance specific

For pregnancy planning, both partners' relevant results may be needed. In alpha-thalassemia, whether deletions lie on the same chromosome or on opposite chromosomes can influence the risk to a child. For beta-related conditions, the particular variants carried by each partner require interpretation together. A generic statement that both partners are “positive” is insufficient to assign the same risk percentage to every couple. GeneReviews: Alpha-Thalassemia, current review NHLBI: Thalassemia and pregnancy

Genetic counseling should describe the possible conditions in a child, the available testing pathways, their timing, and their limitations. It should support informed family decisions without assigning blame. A carrier state is inherited; it is not evidence that either partner did something wrong, and it does not dictate one compulsory reproductive choice. TIF 2023: α-Thalassaemia guideline, summary and recommendations

If pregnancy has already begun, contact obstetric and genetic services promptly so that relevant options can be discussed within their appropriate timeframes. Repeated basic screening without a coordinated plan can consume time while leaving the central inheritance question unanswered. A clinician experienced in hemoglobin disorders can help interpret unusual combinations and arrange appropriate family studies where needed.

After diagnosis, separate organ assessment from repeated diagnostic testing

Patients with clinically significant disease may need baseline assessment beyond the tests that identified thalassemia. The choice depends on age, transfusion exposure, previous complications, and the proposed treatment. Liver iron assessment, cardiac evaluation, endocrine testing, and bone-health assessment serve different purposes. Liver iron MRI and assessment of cardiac iron are not routine entry tests for every healthy carrier; they can be important in people with substantial iron exposure or established disease. Porter, Wood and Coates: Iron Overload and Chelation, TIF 2025 TIF 2025: Summary of Monitoring Recommendations

Growth rate and pubertal development deserve attention in children. Menstrual history, fertility concerns, glucose regulation, and bone health may become relevant at other stages of life. Planning these assessments does not imply that organ damage is already present. It creates a baseline and helps identify changes for which timely action may be useful. Casale et al.: Growth Abnormalities, Endocrine, and Bone Disease, TIF 2025

Ask which tests are needed now, which will be scheduled during follow-up, and which are unnecessary for the present clinical category. A staged plan can be easier for families to manage and avoids confusing disease confirmation with long-term surveillance.

Preserve transfusion compatibility information separately from the genetic report

Blood groups, extended red-cell antigen information, antibody screens, and previous transfusion reactions help the blood bank provide safer transfusions. They do not identify the person's alpha- or beta-globin genotype. Historical red-cell antibodies remain important even if a later screen does not detect them. Give the receiving hospital the original information whenever care moves between centers or countries. Shah, Wood and Maggio: Blood Transfusion, TIF 2025

For a patient who needs ongoing blood support, these records can influence immediate planning more directly than repeating a broad genetic panel. The diagnostic folder and the blood-bank folder answer different questions, and both should travel with the patient when relevant.

Coordinate diagnostic testing before traveling to China

Send the receiving hospital your previous testing methods and complete genetic findings before arranging travel. Explain whether the visit concerns diagnosis and treatment for an individual or reproductive counseling, because the latter may also require prenatal diagnostic services. China's National Health Commission thalassemia collaboration network offers an official starting point for identifying institutions. Network membership does not establish current acceptance of overseas samples, turnaround times, or foreign-patient arrangements. Confirm sample requirements, analytical coverage, report language, and who will explain the final results. 国家卫生健康委：全国地中海贫血防控协作网，2023

Leave the appointment with a documented next step

Before leaving, ask whether the present conclusion is a carrier state, a confirmed clinically significant disorder, or an unresolved finding. Identify which results are dependable and which may be affected by age, transfusion, or another condition. The next proposed test should have a stated purpose and an explanation of how its result could change care. NHLBI: Thalassemia diagnosis

Marked breathlessness, fainting, or an acutely unwell child requires assessment according to clinical urgency rather than waiting for every molecular result. For a stable person, a clear sequence of investigations is usually more useful than repeated uncoordinated blood draws. The aim is an explanation that connects the laboratory evidence, the patient's actual health, and the decisions the family needs to make. TIF: Guidelines for Transfusion-Dependent β-Thalassaemia, fifth edition, 2025